3 citations
,
December 2000 in “PubMed” This study reports that the compound CS-891 can inhibit 5alpha-reductase activity in the dermal papillae of human hair follicles, suggesting potential for treating androgenetic alopecia.
4 citations
,
August 2021 in “Annals of Translational Medicine” In this study, dihydroartemisinin reduced prostate enlargement and related markers in a rat model of benign prostatic hyperplasia, suggesting its potential as a therapeutic agent.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” This article reviews guidelines and medications for treating benign prostatic hyperplasia but presents no new clinical results.
62 citations
,
January 2004 in “PubMed” This review describes the shift in treating symptomatic benign prostatic hyperplasia from surgery to 5alpha-reductase inhibitor drugs, which may provide symptom relief and alter BPH's progression, but reports no new clinical results.
November 2023 in “Research Square (Research Square)” This animal study found that finasteride, a 5-alpha reductase type 2 inhibitor, decreased dihydrotestosterone levels and c-Fos protein activation in the rat brain, but these effects may diminish after discontinuing the drug.